Most people arrive at this question having already been told the answer by someone with no access to their bloodwork. A friend had a remarkable result on one of them. An advert made the newer one sound categorically better. A telehealth service offered whichever it happened to have in stock.
None of those is a clinical reason, and the honest position is that the two medications are genuinely different tools rather than two brands of the same thing.
What each one actually does
Your gut releases hormones when you eat. They tell the brain you have had enough, slow how quickly the stomach empties, and signal the pancreas to release insulin as blood glucose rises. That system is doing its job continuously, and in a lot of people it is not doing it well.
Semaglutide mimics one of those hormones, GLP-1. It engages a single receptor pathway and holds that signal steady across the week rather than letting it spike and fade around meals. Patients describe the effect less as appetite being suppressed and more as it going quiet. The mental noise around food, the negotiating, the planning of the next meal while still eating the current one, tends to stop.
Tirzepatide engages that same GLP-1 receptor and a second one, GIP. That is a different gut hormone involved in insulin response and in how the body stores and uses fat. Two pathways rather than one is the entire structural difference between the medications, and it is why tirzepatide behaves differently in some people rather than simply more strongly in everyone.
Why “which is stronger” is the wrong question
It is the question almost everyone asks, and it imports an assumption that does not hold: that these medications sit on a single scale from weaker to stronger, and that you should want to be as far along it as your tolerance allows.
The more useful question is which mechanism matches what is actually wrong.
If your central problem is appetite signalling, a medication acting on appetite signalling may be entirely sufficient. If insulin resistance is a prominent feature of your bloodwork, the second pathway becomes a more interesting argument. If you have already had a fair trial of one at an appropriate dose and the response was genuinely poor, that history is real evidence and it should change the plan.
None of that is visible from the outside. It comes from a panel.
The trial that was never actually a trial
A large share of people who believe semaglutide did not work for them were never on a dose that would tell you either way, or were on it for a matter of weeks, or stopped when the nausea of an early dose increase arrived and nobody explained that moving up more slowly was an option.
Before concluding that a medication failed, it is worth establishing that it was given a real opportunity to succeed. Switching away from something that was never properly trialled means you learn nothing, and you may end up on a more expensive medication that was never needed.
What the decision should be built from
At Alluring Age the sequence is the same regardless of which medication is eventually prescribed, and the medication is the last part of it rather than the first.
Thyroid function comes first, because an underactive thyroid makes weight loss substantially harder and is treatable in its own right. Hormones come next: the shift through perimenopause, menopause and andropause changes body composition in ways that no amount of effort quite explains, and it is a common reason weight becomes stubborn in your forties and fifties after a lifetime of it not being. Then metabolic markers, including how your body is handling glucose and insulin. Then body composition, so there is a baseline that distinguishes fat from lean mass before anything begins.
Sometimes that workup finds something that changes the plan entirely. Sometimes it confirms that the appetite signalling really is the problem. Either way the decision is made from evidence rather than from what you came in asking for.
What neither medication does
Neither one addresses why the dysregulation is there. That is the most important sentence on this page.
They are effective at the mechanism they act on and they do not touch the cause underneath it. If an untreated thyroid problem is part of your picture, the weight will come off and the fatigue will not resolve. If the driver is hormonal, it is still there. When the medication stops, appetite signalling returns to roughly where it was, and if nothing else changed in the meantime, the weight tends to follow.
That is not an argument against the medications. It is an argument against treating them as the whole plan, which is precisely what the cheapest versions of this do.
Muscle is the part nobody mentions
Weight coming off quickly costs lean mass unless it is deliberately defended. Muscle is metabolically active tissue, so losing it lowers the rate at which you burn energy at rest and makes regaining the weight easier later. Losing thirty pounds where a meaningful share was muscle leaves you lighter and metabolically worse off than you started.
Adequate protein, resistance training, and tracking body composition rather than the scale alone are how that is managed. It is also why a number on a scale is a poor way to judge whether any of this is working. Two people down the same weight can have had opposite outcomes, and only one of them will hold it.
We have written separately about protecting lean mass while the weight comes down.
Side effects, honestly
Both medications share a side effect profile that is mostly gastrointestinal: nausea, vomiting, diarrhoea, constipation. These are most likely while the dose is being increased and usually settle. The single most common reason people have a miserable time is escalating too quickly, which is a supervision problem rather than a property of the drug.
Both carry less common but more serious risks, including pancreatitis and gallbladder problems. Both carry a boxed warning regarding thyroid C-cell tumours observed in rodent studies, and both are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or of multiple endocrine neoplasia syndrome type 2. Neither is appropriate in pregnancy or while breastfeeding.
Anyone who describes these as side-effect-free is not someone to take medical advice from.
What to ask before you start
Whoever you see, and whether or not that is us, these are worth asking:
- What bloodwork will you run before prescribing, and what would change your recommendation?
- Am I getting the brand-name medication or a compounded version, and what is the difference here?
- How quickly will the dose be increased, and what happens if I do not tolerate it?
- How will we know whether I am losing fat rather than muscle?
- What is the plan for when I stop?
A provider who has good answers to all five is worth more than one offering the lowest monthly price, because the difference between those two propositions is the part that determines whether you keep the result.
If you would like the question answered against your own results rather than in general, that is what a consultation is for.
